Clinical Research Directory
Browse clinical research sites, groups, and studies.
Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study
Sponsor: Centre Hospitalier de Valenciennes
Summary
Pneumonia are the most frequent infections in ICU. Little is known about beta-lactam doses necessary for this infection for patients treated with continuous veino-veinous hemodialysis. The pharmacokinetic variability expose to over and underdosage leading to toxicity or therapeutic failure. The aim of this study is to define if beta-lactams doses used in pneumonia for patients with acute kidney injury treated with our hemodialysis conditions lead to beta-lactam therapeutic plasma levels.
Official title: Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
65
Start Date
2019-02-22
Completion Date
2026-05-31
Last Updated
2024-02-02
Healthy Volunteers
No
Locations (1)
Centre Hospitalier de Valenciennes
Valenciennes, Nord, France